These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 16098850

  • 1. Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21.
    Nicolaides KH, Chervenak FA, McCullough LB, Avgidou K, Papageorghiou A.
    Am J Obstet Gynecol; 2005 Aug; 193(2):322-6. PubMed ID: 16098850
    [Abstract] [Full Text] [Related]

  • 2. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies.
    Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2002 Sep; 20(3):219-25. PubMed ID: 12230441
    [Abstract] [Full Text] [Related]

  • 3. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O, Auer M, Gerovassili A, Spencer K, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [Abstract] [Full Text] [Related]

  • 4. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
    Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O.
    Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
    [Abstract] [Full Text] [Related]

  • 5. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
    Ardawi MS, Nasrat HA, Rouzi AA, Qari MH, Al-Qahtani MH, Abuzenadah AM.
    Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
    [Abstract] [Full Text] [Related]

  • 6. First trimester predictors of adverse pregnancy outcomes.
    Brameld KJ, Dickinson JE, O'Leary P, Bower C, Goldblatt J, Hewitt B, Murch A, Stock R.
    Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
    [Abstract] [Full Text] [Related]

  • 7. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
    Marsk A, Grunewald C, Saltvedt S, Valentin L, Almström H.
    Acta Obstet Gynecol Scand; 2006 Dec; 85(5):534-8. PubMed ID: 16752230
    [Abstract] [Full Text] [Related]

  • 8. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
    [Abstract] [Full Text] [Related]

  • 9. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO, Wright D, Maiz N, Pandeva I, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
    [Abstract] [Full Text] [Related]

  • 10. Clinical first-trimester routine screening for Down syndrome in singleton pregnancies in northern Finland.
    Valinen Y, Rapakko K, Kokkonen H, Laitinen P, Tekay A, Ahola T, Ryynanen M.
    Am J Obstet Gynecol; 2007 Mar; 196(3):278.e1-5. PubMed ID: 17346554
    [Abstract] [Full Text] [Related]

  • 11. Effect of maternal smoking on prenatal screening for Down syndrome and trisomy 18 in the first trimester of pregnancy.
    Miron P, Côté YP, Lambert J.
    Prenat Diagn; 2008 Mar; 28(3):180-5. PubMed ID: 18264956
    [Abstract] [Full Text] [Related]

  • 12. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
    Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH.
    Hum Reprod; 2008 Sep; 23(9):1968-75. PubMed ID: 18544579
    [Abstract] [Full Text] [Related]

  • 13. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).
    Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, Hankins G, Berkowitz RL, Merkatz I, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Vidaver J, D'Alton ME.
    Am J Obstet Gynecol; 2004 Oct; 191(4):1446-51. PubMed ID: 15507981
    [Abstract] [Full Text] [Related]

  • 14. Comparison of serum markers in first-trimester down syndrome screening.
    Canick JA, Lambert-Messerlian GM, Palomaki GE, Neveux LM, Malone FD, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Saade GR, Berkowitz RL, Dar P, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME, First and Second Trimester Evaluation of Risk (FASTER) Trial Research Consortium.
    Obstet Gynecol; 2006 Nov; 108(5):1192-9. PubMed ID: 17077242
    [Abstract] [Full Text] [Related]

  • 15. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
    Spencer K, Cowans NJ, Avgidou K, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2006 Oct; 28(5):637-43. PubMed ID: 16952214
    [Abstract] [Full Text] [Related]

  • 16. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.
    Krantz D, Goetzl L, Simpson JL, Thom E, Zachary J, Hallahan TW, Silver R, Pergament E, Platt LD, Filkins K, Johnson A, Mahoney M, Hogge WA, Wilson RD, Mohide P, Hershey D, Wapner R, First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group.
    Am J Obstet Gynecol; 2004 Oct; 191(4):1452-8. PubMed ID: 15507982
    [Abstract] [Full Text] [Related]

  • 17. First-trimester screening for trisomy 21 in twin pregnancy: does the addition of biochemistry make an improvement?
    Goncé A, Borrell A, Fortuny A, Casals E, Martínez MA, Mercadé I, Cararach V, Vanrell JA.
    Prenat Diagn; 2005 Dec; 25(12):1156-61. PubMed ID: 16231401
    [Abstract] [Full Text] [Related]

  • 18. Serum PAPP-A levels at 10-14 weeks of gestation are altered in women after assisted conception.
    Tul N, Novak-Antolic Z.
    Prenat Diagn; 2006 Dec; 26(13):1206-11. PubMed ID: 17075793
    [Abstract] [Full Text] [Related]

  • 19. [Effect of maternal smoking on concentrations of the pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of chorionic gonadotropin (beta hCG) in the first trimester of pregnancy].
    Gajewska J, Ceran A, Chełchowska M, Borowski D, Ambroszkiewicz J, Jaczyńska R, Zwoliński J, Laskowska-Klita T.
    Przegl Lek; 2008 Dec; 65(10):479-82. PubMed ID: 19189527
    [Abstract] [Full Text] [Related]

  • 20. Is there a nuchal translucency millimeter measurement above which there is no added benefit from first trimester serum screening?
    Comstock CH, Malone FD, Ball RH, Nyberg DA, Saade GR, Berkowitz RL, Ferreira J, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Bianchi DW, D'Alton ME, FASTER Research Consortium.
    Am J Obstet Gynecol; 2006 Sep; 195(3):843-7. PubMed ID: 16949423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.